Waisbren B A
J Biol Response Mod. 1987 Feb;6(1):1-19.
Herein are reported the results of treating 139 cancer patients with combined immunomodulation that consisted of bacillus Calmette-Guerin, transfer factor, and mixed bacterial vaccine. In addition 28 patients were given infusions of lymphoblastoid lymphocytes. Patients were admitted to this treatment program who either had failed to respond to other modalities, had elected to add immunomodulation to usual therapy, or had refused chemotherapy and/or radiation therapy. The results suggested that combined immunomodulation therapy is well tolerated and safe and that this approach on a prima facie basis had a salutary effect on the courses of a number of the patients treated. The results also illustrate alternative pathways that can be taken by patients and physicians who are not comfortable with protocolized double-blind methods of approaching patients with poor prognosis cancer.
本文报告了采用卡介苗、转移因子和混合菌苗组成的联合免疫调节疗法治疗139例癌症患者的结果。此外,28例患者接受了淋巴母细胞输注。接受该治疗方案的患者,要么是对其他治疗方式无反应,要么是选择在常规治疗基础上加用免疫调节,要么是拒绝化疗和/或放疗。结果表明,联合免疫调节疗法耐受性良好且安全,初步看来,这种方法对许多接受治疗的患者病程有有益影响。结果还说明了对于那些不适应采用标准化双盲方法治疗预后不良癌症患者的患者和医生而言,可以采取的其他途径。